Alejandro Martín García-Sancho
Hospital Universitario Salamanca
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alejandro Martín García-Sancho as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07254754 · Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · recruiting · DIFFUSE LARGE B-CELL LYMPHOMA · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 11:09 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).J Clin Oncol · 2022178 citationsRCR 11.4
- 66 citationsRCR 4.8
- Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.Blood Adv · 202324 citationsRCR 2.0
- 10 citationsRCR 5.0